Medtronic’s IN.PACT AV Access trial meets effectiveness endpoints
Category: #health  By Mateen Dalal  Date: 2019-09-09
  • share
  • Twitter
  • Facebook
  • LinkedIn

Medtronic’s IN.PACT AV Access trial meets effectiveness endpoints

IN.PACT AV DCB showed encouraging results in the treatment of AV Fistulae Lesions in Renal Disease Patients at its last stage.

Medtronic plc, one of the world’s biggest medical device companies, has recently announced outcomes from its IN.PACT AV Access clinical trials assessing the PTA (percutaneous transluminal angioplasty) against the IN.PACT™ AV™ DCB (drug-coated balloon) in subjects with non-stented or de novo restenotic AV (arteriovenous) fistulae lesions.

Reportedly, the trials recently achieved its effectiveness endpoints and primary safety, presenting the data at the CIRSE (Cardiovascular and Interventional Radiology Society of Europe) annual meeting in Spain.

Speaking on the move, Andrew Holden, M.D., Associate Professor of Radiology at Auckland University and Director of Interventional Radiology at Auckland Hospital, said that limiting the frequency and maintaining patency of reinterventions demanded AV access sites to properly function remains the major treatment challenges for physicians doctoring AV fistulae lesions.

He said that these results show the potential of IN.PACT AV DCB in addressing these crucial issues and in improving the quality of life of patients going through dialysis.

For the uninitiated, AV fistulae, also known as AV access sites, was developed and used to provide hemodialysis to patients with ESRD (end-stage renal disease). As time passes, vessel restenosis restricts the capability to use AV fistulae efficiently. Hence, in order to rebuild function, patients frequently go through several AV fistula maintenance procedures each year. 

However, the need for repeated reinterventions can lead to a major disruption in serious hemodialysis care and would raise the costs of the healthcare system. Additionally, drug-coated balloons could extend the time between reinterventions by sustaining AV access site patency, increasing the patient’s constant access to dialysis care.

According to sources, the primary effectiveness endpoint reduced CD-TLR (clinically-driven target lesion revascularization). Moreover, additional endpoints involved collective target lesion revascularization, a number of interventions needed to sustain target lesion patency and access circuit primary patency.

Source Credit: http://newsroom.medtronic.com/news-releases/news-release-details/inpact-av-access-trial-meets-primary-safety-and-effectiveness

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

A qualified electronics and telecommunication engineer, Mateen Dalal embarked on his professional journey working as a quality and test engineer. Harnessing his passion for content creation however, Mateen pens down industry-rich articles for ReportsGO.com and a few o...

Read More

More News By Mateen Dalal

Omnicell to present its newest innovations in medication management
Omnicell to present its newest innovations in medication management
By Mateen Dalal

Omnicell, Inc., a U.S. based company that offers adherence tools for healthcare systems and pharmacies along with medication management solutions, has recently revealed that it would be presenting its medication management portfolio’s latest de...

MyndVR-Vi unite to deliver VR care services at Palo Alto CCRCs
MyndVR-Vi unite to deliver VR care services at Palo Alto CCRCs
By Mateen Dalal

MyndVR, a leading health and wellness company providing virtual reality solutions to senior living communities, has recently announced its partnership with Vi. Vi is a leading continuing care retirement community (CCRC), which integrates sophisticate...

Quest Diagnostics announces acquisition of Blueprint Genetics
Quest Diagnostics announces acquisition of Blueprint Genetics
By Mateen Dalal

Quest Diagnostics announced the acquisition of genetic testing firm, Blueprint Genetics to extend access to actionable insights in genetic and rare diseases. The acquisition is aimed at enhancing patient care and boosting research and development of ...